1. 11/8/2016 Definiens Launches Cloud­based Digital Pathology Solution VeriTrova™ to Support Takeda’s Translational and Biomarker Research Efforts | Definiens
http://www.definiens.com/about­us/press/press­releases/press­release­definiens­launches­cloud­based­digital­pathology­solution­veritrova­to­support­takedas… 1/2
Lit of Pre Releae (/aout-u/pre/pre-releae)b
De nien Launche Cloud-aed Digital Patholog olution
VeriTrova to upport Takeda’ Tranlational and iomarker Reearch
 ort
New olution Help Accelerate Clinical Trial
Munich, German – Nov 7 2016 – De nien (http://www.de nien.com/), the leader in Tiue Phenomic olution
from iomarker dicover to meaningful diagnotic, toda announced a program collaoration with Takeda
Pharmaceutical to enale comprehenive tiue-aed anali in clinical trial.
De nien’ product and ervice deepen the undertanding of dieae iolog and the immune tem to advance
clinical trial.  uing knowledge-driven iomarker anali in comination with VeriTrova , the compan’ new
cloud-aed digital patholog platform, De nien eamlel tranlate reearch to clinical knowledge to the next
generation of diagnotic.
A an earl adopter of De nien’ VeriTrova, Takeda will have the opportunit to leverage the platform to upport it
development program.
“VeriTrova accelerate clinical trial through remote uploading and viewing of digitized IHC image from wet-la
partner and CRO to the cloud, where the image are analzed,” a Thoma Colaruo, VP uine Development
and trateg at De nien.
The real-time anali i expected to help Takeda reduce normal procee from month to week, with image
anali providing a more automated and tandardized readout.
“Takeda i dedicated to operational excellence and delivering high qualit reult in our clinical tudie,” a Andrew
Dorner, VP and Gloal Head of Tranlational Medicine at Takeda. “We expect thi tem will improve the timeline
and qualit of our image anali for clinical iomarker.”
For more information aout De nien, viit www.de nien.com (http://ct.uinewire.com/ct/CT?
id=martlink&url=http%3A%2F%2Fwww.de nien.com&eheet=51392193&newitemid=20160802005055&lan=en-
U&anchor=www.de nien.com&index=3&md5=4ad5c07cf422165910f93c0dd430e3).
Aout De nien
™
®
™
Pre Releae

2. 11/8/2016 Definiens Launches Cloud­based Digital Pathology Solution VeriTrova™ to Support Takeda’s Translational and Biomarker Research Efforts | Definiens
http://www.definiens.com/about­us/press/press­releases/press­release­definiens­launches­cloud­based­digital­pathology­solution­veritrova­to­support­takedas… 2/2
We improve patient live  unlocking the tiue phenome. In oncolog, therapeutic trategie have hi ed from a
direct aault on cancer cell to recruiting the immune tem for that purpoe. Our miion i to accelerate
reakthrough for thi approach  helping cientit leverage Tiue Phenomic to deepen undertanding of
dieae iolog and immune tem mechanim, to ring multi-omic data into a cancer-relevant context, and to
facilitate the tranlation of new inight into novel therapie and treatment trategie. Our viion i to create unique
patient pro le for an individualized tandard of care, where patient experience fewer ide e ect and live longer.
De nien' Tiue Phenomic approach wa awarded the 2013 Frot and ullivan Compan of the Year Award for
Gloal Tiue Diagnotic and Patholog Imaging. For more information, pleae viit: www.de nien.com.
Media Contact
A ect
Melia aratta
+1 212-398-9680
maratta@a ect.com (mailto:maratta@a ect.com)
   
Imprint Term of Ue
Privac Polic Data Protection Polic
Contact
© De nien 2016
ngineered  Audacit (http://audacithealth.com)